-- Announcement on Resolutions of the 24th (Extraordinary) Meeting of the 8th Board of Directors
Securities code: 600420 Securities abbreviation: Sinopharm Modern Announcement number: 2025-075
Shanghai Modern Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 24th (Extraordinary) Meeting of the Eighth Board of Directors
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
1. Convening of board of directors meetings
The 24th (temporary) meeting of the eighth board of directors of Shanghai Modern Pharmaceutical Co., Ltd. (hereinafter referred to as the company) was held on September 22, 2025 by means of communication voting. Notice and information for this meeting have been sent out via email on September 16, 2025. There were 8 directors who were supposed to attend this meeting, but 8 directors actually attended. The meeting was convened in compliance with the relevant provisions of the Company Law and the Articles of Association, and was legal and valid.
2. Review status of board of directors meeting
This meeting reviewed and approved the following matters:
- The "Proposal on the Election of Vice Chairman" was reviewed and approved.
Voting results: 8 votes in favor, 0 votes against, and 0 abstentions.
It was agreed to elect Mr. Cai Maisong as the vice chairman of the eighth session of the Board of Directors of the company, with a term of office that will expire when the current session of the Board of Directors expires. (Resume attached)
- The "Proposal on Adding Members to the Strategy and Investment Committee of the Board of Directors" was reviewed and approved.
Voting results: 8 votes in favor, 0 votes against, and 0 abstentions.
It was agreed to add Mr. Cai Maisong as a member of the Strategy and Investment Committee of the eighth session of the Board of Directors of the company, with his term ending at the expiration of the current session of the Board of Directors.
- The "2025 Internal Control System Construction and Supervision and Evaluation Work Plan" was reviewed and approved.
Voting results: 8 votes in favor, 0 votes against, and 0 abstentions.
Announcement is hereby made.
Board of Directors of Shanghai Modern Pharmaceutical Co., Ltd.
September 23, 2025
Securities code: 600420 Securities abbreviation: Sinopharm Modern Announcement number: 2025-075
Attachments:
Cai Maisong, male, born in 1970, holds a bachelor’s degree in pharmacy and a master’s degree in business administration. He has worked in Guangzhou Baiyunshan Pharmaceutical Factory, French Servier Pharmaceutical Factory, China National Pharmaceutical Group Tianjin Purchasing and Supply Station and China National Pharmaceutical Group Tianjin Company. He has successively served as Director of the Commercial Department and Director of the Operations Management Center of Sinopharm Holdings Tianjin Co., Ltd.; Director of the Risk and Operations Management Department of Sinopharm Holdings Co., Ltd.; Deputy Director, Director and Deputy Director of the Policy Research Office of the Risk and Operations Management Department of China National Pharmaceutical Group Corporation; and Deputy Director of the Sichuan Provincial Food and Drug Administration (temporary position). Currently, he is the vice president of Sinopharm Holdings Co., Ltd. and director of Shanghai Modern Pharmaceutical Co., Ltd.